Loading...
Surgery Partners delivered strong revenue growth in Q4 2024, increasing 17.5% year-over-year. However, the company reported a net loss of $108.5 million due to a non-cash tax valuation allowance. Adjusted EBITDA grew to $163.8 million, reflecting continued operational improvements.
Revenue grew 17.5% YoY to $864.4 million.
Net loss was $108.5 million, impacted by a non-cash tax valuation allowance.
Adjusted EBITDA increased 15.1% to $163.8 million.
Same-facility revenues grew 5.6%, driven by case volume growth.
Surgery Partners projects revenue growth for 2025, targeting up to $3.45 billion with strong EBITDA expansion.